• AQP protein expression was determined by Western blot

  2021-08-10

  

  AQP4 protein expression was determined by Western blot analysis. Briefly, protein samples (50μg) from brains or astrocytes were separated by 12% SDS–polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were reacted with a rabbit polyclonal antibody against AQ

• The CYP D inferred metabolizer phenotype describes

  2021-08-10

  

  The CYP2D6-inferred metabolizer phenotype describes only one phase of the tramadol (T) ADME (absorption, distribution, metabolism, and excretion) and response process and does not explain all genotypic contribution of an individual’s phenotypic expression [11]. Numerous polymorphisms in the downstre

• Binding affinity was measured by

  2021-08-10

  

  Binding affinity was measured by a scintillation proximity binding assay using [H]4-OHT (ERRγ) or [H]estradiol (ERα/β) as radioligand. In all cases, the ERβ affinity was not significantly different from ERα. Compounds were compared to , which showed high affinity for both receptors and moderate (six

• br Methods and materials br Results br Discussion Many

  2021-08-10

  

  Methods and materials Results Discussion Many small molecules have been individually explored to enhance endothelial barrier both in vitro and in vivo, including S1P, forskolin, cAMP analogs, ROCK inhibitors, statins, and imatinib [[10], [11], [12],25,26]. In the current study, we applied t

• TKI discontinuation studies demonstrate that a portion of

  2021-08-10

  

  TKI discontinuation studies demonstrate that a portion of TKI-treated CML patients remain in remission for up to 3 years, although long-term risk assessment is still necessary (Bansal and Radich, 2016). The majority of CML patients depend on lifetime TKI treatment, and substantial efforts have been

• br Experimental Procedures br Author

  2021-08-09

  

  Experimental Procedures Author Contributions Acknowledgments Research in the Davis laboratory was supported by grants 4R37NS019904, 5R01NS052351, and 1R35NS097224 from NINDS. Research in the Martemyanov laboratory was supported by grants DA036596 and DA026405 from NIDA, and MH105482 from NI

• sphingosine kinase In addition we investigated if the previo

  2021-08-09

  

  In addition, we investigated if the previously reported papain inhibitor can inhibit rhodesain, and found that it was not active at inhibiting rhodesain. The vinyl sulfone analogue of () was then synthesized and tested, and it was also inactive towards rhodesain. We then determined the time depend

• Alvocidib flavopiridol is a piperidine chromenone http

  2021-08-09

  

  Alvocidib (flavopiridol) is a piperidine-chromenone derivative (Fig. 6D) that is not FDA approved, but is in clinical trials for breast, endometrial, and several other cancers and hematological malignancies (Table 4) [[100], [101], [102], [103], [104]]. This drug targets CDK9 (IC50 = 3.2 nM) and CDK

• To ascertain that the slower migrating bands represented pho

  2021-08-09

  

  To ascertain that the slower migrating bands represented phosphorylated CDK5, we performed a phosphatase assay. Lysates of Tasquinimod mg co-expressing p35 and either WT or D144N CDK5 were immunoprecipitated using an anti-p35 antibody. The immunoprecipitates were then dephosphorylated using SAP alon

• While several C terminal peptides have been reported to

  2021-08-09

  

  While several C-terminal peptides have been reported to have modest (astressin) or substantial (astressin2-B, antisauvagine-30) subtype selectivity for the CRF2 receptor (), [125I]YP20 is the first reported small analog of the C-terminus of CRF exhibiting subtype selectivity for the CRF1 receptor vs

• In the current study we

  2021-08-09

  

  In the current study, we monitored different groups at risk for CMV reactivation. Similar to the findings from other groups, we observed CMV-reactivations with high-level viremia mostly during the first three months after alloHSCT only in the (D−/R+) and (D+/R+) group [[23], [24]]. Increasing IFN‐γ

• Cy3 maleimide (non-sulfonated) Recently several Pt IV comple

  2021-08-09

  

  Recently, several Pt(IV) complexes as prodrugs have been designed and studied to enhance anti-tumor efficacy of traditional Pt(II) drugs, improving their cellular uptake and blood-circulation time [26], [27], [28], [29]. Compared with their Pt(II) counterparts, six-coordinated Pt(IV) complexes with

• br Cholesterol handling in the arterial

  2021-08-09

  

  Cholesterol handling in the arterial wall cells Foam cell formation in the arterial intima is a major hallmark of early-stage atherosclerotic lesions, which is attributed to uncontrolled uptake of modified lipoproteins, excess cholesterol esterification and impaired cholesterol release [44]. As a

• Ro3280 Patients and methods This study

  2021-08-09

  

  Patients and methods This study was performed at 3 academic centers (Chung-Ang University YongSan Hospital, Soonchunhyang University Hospital, and Chung-Ang University Hospital) in Seoul, Korea, from November 2008 to November 2010. The study protocol was approved by the institutional review boards

• Functional studies revealed that these

  2021-08-09

  

  Functional studies revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is active in absence of estrogen, conferring resistance against several endocrine agents. Recent studies reported that the occurrence of ESR1 mutations is rare in ER+ primary brea

11116 records 302/742 page Previous Next First page 上5页 301302303304305 下5页 Last page